
Humpback Whales May Not See Their Most Dangerous Threats
Run-ins with humans are the leading cause of death for humpback whales — and new research may explain why these gentle giants are so vulnerable to collisions with boats and entanglement in fishing nets.
The softball-size eyes of humpbacks offer shockingly poor vision, according to a study published Wednesday in the journal Proceedings of the Royal Society B. Unfortunately, this isn't the kind of vision issue that can be corrected with a prescription (as much as we'd all like to see a whale in glasses).
Simulations indicate whales see most of their surroundings in shadowy silhouettes and struggle to resolve fine-scale details until they're extremely close, said Jacob Bolin, who conducted the study while completing his marine biology degree at the University of North Carolina Wilmington. That means the spidery lines of fishing nets may be virtually invisible to humpbacks until it's too late to avoid them.
Better understanding how humpbacks and other whales see could inspire 'strategies for making fishing gear more visible' and help the whales avoid deadly encounters with humans, said Lorian Schweikert, a sensory biologist also at the University of North Carolina-Wilmington and an author of the paper.
To understand humpback vision, Mr. Bolin and his team dissected the eye of a juvenile humpback whale that died on a North Carolina beach in 2011. While most whales that wash ashore have been dead for weeks and are badly decomposed, this individual was euthanized on land. That afforded scientists an opportunity to study humpback anatomy.
Having such large eyes should, based on optical principles, be an asset: the longer the focal distance, or the length between the lens and the retina, the sharper the image, Mr. Bolin explained. But the researchers found that more than a third of the eye's depth was taken up by meaty sclera, the white of the eye that's not involved in vision.
But the greatest limiting factor for the whale's vision is the low density of retinal ganglion cells, which Mr. Bolin compared to 'the pixels of the eye.' The cells capture the image reflected on the retina and convert it into electrical signals the brain can understand. Denser retinal ganglia mean a higher-resolution picture arrives to the brain.
The highest density Mr. Bolin tallied in the whale's eye was about 180 retinal ganglia per square millimeter. Humans can have about 35 to 40,000 per square millimeter, while keen-eyed birds of prey can have up to 70,000 in the same area.
To see how these anatomical features work together, the researchers used software to simulate how underwater scenes might look to humpbacks, which scientists already knew see only in black and white. They modeled two images that are important to whales navigating the modern seas — a school of small fish, and a commercial fishing net — at various distances.
The results suggest a significant drop-off in perception of objects at a distance of around 150 feet to 200 feet — not so far considering adult humpbacks are about 45 feet long. While the school of fish was reduced to a hazy blob, the gillnet became almost invisible.
It's not just that humpbacks will struggle to identify a more distant object — they might not even realize it's there, Dr. Schweikert said.
These findings crystallize just how poor the humpback's vision is, said Dr. Elena Vecino Cordero, an ophthalmologist at the University of the Basque Country in Spain who has studied whale eyes and wasn't involved in the study.
In fact, Mr. Bolin's estimates of whale vision might even be too rosy, Dr. Vecino said — her analysis of three other baleen whale species found even lower densities of retinal ganglia. Dr. Vecino and Mr. Bolin agree that the North Carolina whale's eyeball might have shrunk slightly in the 12 years it spent preserved in a jar before Mr. Bolin dissected it, which would have led him to overestimate their sight.
But how do humpbacks get along with such poor vision? Frankly, before the seas were filled with human infrastructure like boats and nets, they never needed it, Dr. Schweikert said. Adult humpback whales don't really have predators to look out for, and researchers believe they rely on other senses, including smell, to detect their prey. Unlike their cousins the toothed whales, humpbacks can't echolocate.
'Our justifiable fascination for whale song and sonar has left us with few clear answers on what those huge eyes are for,' said Sönke Johnsen, a biology professor at Duke University and an author of the study.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Health Line
an hour ago
- Health Line
What's the Life Expectancy for Parkinson's Disease?
Key takeaways At age 65, patients with Parkinson's disease have a life expectancy reduced by 6.7 years compared to those without the disease, while at age 85, the difference in life expectancy is 1.2 years. Severe clinical milestones that can impact survival include visual hallucinations, recurrent falls, dementia, and placement in a nursing home. Each milestone may double the risk of death during a 10-year period. Males with Parkinson's disease may experience a greater reduction in life expectancy than females, and those diagnosed before age 70 typically see a larger decrease in life expectancy compared to later diagnoses. If you or a loved one has received a diagnosis of Parkinson's, you may be wondering how the disease may progress over time. Parkinson's disease is a slow, progressive disease. This means that symptoms gradually worsen over time. While Parkinson's disease itself isn't fatal, related complications can reduce life expectancy. The individual outlook can vary based on the severity of Parkinson's disease, a person's overall health, and the type of Parkinson's disease they have. Research from 2020 suggests that at 65 years, the life expectancy of patients with Parkinson's was reduced by 6.7 years compared to that of people without Parkinson's disease. At 85, the difference in life expectancy was 1.2 years. Keep reading to learn more about the disease course and outlook with Parkinson's disease and the factors that may inform a doctor's prediction about a person's outlook. Factors that affect the outlook with Parkinson's disease Symptoms and complications can affect the outlook of a person with Parkinson's disease. Symptoms and severity Research from 2022 suggests that the presence of certain severe clinical milestones may predict a person's disease course with Parkinson's disease and increase the risk of death. Each milestone may double the risk of death during a 10-year period. These milestones include: visual hallucinations recurrent falls dementia placement in a nursing home Parkinson's and falls Falls are a common secondary symptom of Parkinson's disease. The risk of falling increases in stages 3 and is greater in stages 4 and 5. In these stages, you may not be able to stand or walk on your own. You'll also be prone to broken bones and concussions, and severe falls can be dangerous. Complications from a serious fall can reduce your life expectancy. Age Age is another factor in the diagnosis and outlook for Parkinson's disease. Most people will receive a diagnosis after 70. As you get older, you may be more prone to falls and more likely to develop certain diseases, even if you don't have Parkinson's disease. These risks can increase if you have Parkinson's. Research from 2020 suggests that people who receive a diagnosis before age 70 usually experience a greater reduction in life expectancy: In people at age 55: a 10.1-year reduction In people at age 65: a 6.7-year reduction In people at age 75: a 3.5-year reduction In people at age 85: a 1.2-year reduction Sex Research suggests that males with Parkinson's may have a greater reduction in life expectancy than females. Access to treatment Life expectancy has increased significantly due to advances in treatment. Medications and physical and occupational therapy are especially helpful in the earliest stages of Parkinson's. These treatments can improve your quality of life. Type of disease The type of parkinsonism can also impact a person's life expectancy, according to 2020 research. People with atypical parkinsonism, including Lewy body dementia, progressive supranuclear palsy, and multiple system atrophy, have increased mortality compared to people with typical Parkinson's disease and people without Parkinson's disease. Long-term outlook Early detection of Parkinson's disease is key to helping reduce complications that can negatively affect the outlook. If you suspect that you or a loved one may have Parkinson's disease, consult a doctor right away. Parkinson's symptoms and severity by stage Doctors classify Parkinson's disease into stages 1 to 5, with stage 5 being the most advanced. Advanced stages may increase the risk of health complications that can reduce life span. The symptoms of Parkinson's are gradual and are sometimes not noticeable in the early stages of the disease. They may include: tremors loss of balance slowing of movements spontaneous, uncontrollable movements Symptoms in later stages of Parkinson's may include: more frequent falls trouble dressing difficulty eating swallowing severe stiffness in your legs, which makes it impossible to stand or walk hallucinations or delusions cognitive changes (problems with planning, language, attention, or memory) dementia lightheadedness mood disorders loss of sense of smell or taste vision problems sleep disorders sexual problems As Parkinson's progresses to stages 3, 4, and 5, the risk of falling may increase, and motor balance may worsen. Pneumonia, particularly aspiration pneumonia, is the leading cause of death for people with Parkinson's, accounting for 70% of Parkinson's deaths. Aspiration pneumonia happens when you inhale food, stomach acid, or saliva into the lungs. As Parkinson's progresses, swallowing can become more difficult, causing food and liquid to enter the lungs. Treatment may help reduce symptoms. Frequently asked questions Why does it take so long for a diagnosis of Parkinson's disease? There is no definitive medical test that can be performed to diagnose Parkinson's disease. It's essentially a clinical diagnosis, meaning a doctor will make the diagnosis based on several clinical features seen. Symptoms of Parkinson's disease include tremor, slowness of movement, stiffness, and balance problems. However, the presentation and progression of these symptoms vary widely from person to person. The initial presentation is often subtle and may be similar to other conditions. Some people think their symptoms are due to normal aging, which may make them delay seeking medical attention. Another common finding in patients with Parkinson's disease is 'masked facies,' or an expressionless face, which often gets mistaken for depression. If there's concern that someone is developing Parkinson's disease, they should get a clinical exam from a neurologist to get a diagnosis. There is no definitive medical test that can be performed to diagnose Parkinson's disease. It's essentially a clinical diagnosis, meaning a doctor will make the diagnosis based on several clinical features seen. Symptoms of Parkinson's disease include tremor, slowness of movement, stiffness, and balance problems. However, the presentation and progression of these symptoms vary widely from person to person. The initial presentation is often subtle and may be similar to other conditions. Some people think their symptoms are due to normal aging, which may make them delay seeking medical attention. Another common finding in patients with Parkinson's disease is 'masked facies,' or an expressionless face, which often gets mistaken for depression. If there's concern that someone is developing Parkinson's disease, they should get a clinical exam from a neurologist to get a diagnosis. Is Parkinson's disease fatal? While Parkinson's disease is not fatal, it can cause complications that increase the risk of death. People with Parkinson's have a mortality rate 3 times that of people without Parkinson's. While Parkinson's disease is not fatal, it can cause complications that increase the risk of death. People with Parkinson's have a mortality rate 3 times that of people without Parkinson's. Can treatment help prevent Parkinson's disease complications? Parkinson's disease cannot be cured, but medications, supportive treatments, lifestyle changes, and even surgery can help manage your symptoms or delay more severe symptoms, especially if you start treatment early. This may reduce complications. Parkinson's disease cannot be cured, but medications, supportive treatments, lifestyle changes, and even surgery can help manage your symptoms or delay more severe symptoms, especially if you start treatment early. This may reduce complications.


Gizmodo
an hour ago
- Gizmodo
In the Feud Between Trump and Musk, NASA Has a Lot to Lose
The SpaceX CEO threatened to pull his Dragon spacecraft, flaunting an incredible amount of leverage. In the heat of the moment, Elon Musk threatened to decommission SpaceX's Dragon spacecraft and then he took it back. In doing so, however, the rocket billionaire dragged NASA into his messy breakup with Donald Trump, with the agency's access to orbit now at stake. Musk and Trump parted ways earlier this week, and their breakup has been very messy. Shortly after leaving the administration, Musk began criticizing the budget bill passed by Republicans in the U.S. House, instigating a public feud between the president and the billionaire oligarch. The childish back-and-forth was entertaining, until it wasn't. 'SpaceX will begin decommissioning its Dragon spacecraft immediately,' Musk threatened on X. He later took another X user's advice to 'cool off,' and wrote, 'Ok, we won't decommission Dragon.' Although short-lived, the threat put the International Space Station (ISS) at risk. NASA relies heavily on SpaceX's Dragon to transport its astronauts and cargo supplies to the orbiting lab, having weaned itself from hitching rides aboard Russia's Soyuz spacecraft. SpaceX's closest alternative, Boeing, failed miserably at proving its vehicle's capability to reach the ISS safely. Without Dragon, NASA would lose its access to low Earth orbit and not be able to operate the space station at the same capacity. It's not clear how serious Musk was in his threat, but it was a serious display of leverage on his part. SpaceX is no doubt a leader in the industry, and canceling its government contracts would hurt the national space program, which has come to rely on the private sector in recent years. In response to Musk's clear advantage, Steve Bannon, Trump's former chief strategist, called on the president to nationalize SpaceX under a 1950 law known as the Defense Production Act, according to The Wall Street Journal. During his show, War Room Live, Bannon urged the use of the Korean War-era law which grants the president powers to prioritize national defense. The plan might seem outrageous now, but the current administration is unpredictable. Trump has yet to respond to Bannon's call. If he doesn't move to nationalize SpaceX, Trump could also sacrifice NASA for the sake of proving a point against his now opponent, Musk. On Thursday, Trump threatened to cut government contracts given to SpaceX. Aside from Dragon, NASA also plans on using SpaceX's Starship rocket to launch astronauts to the Moon as part of the Artemis program. The agency has already invested $4 billion into the rocket's development, and canceling its contract with SpaceX would leave it without a viable alternative. In short, NASA needs SpaceX and canceling the company's government contracts would affect the national space program as a whole. At this point, it comes down to how much Trump is willing to sacrifice in order to gain the upper hand in his ongoing feud with Musk while NASA is caught in the middle.


Medscape
an hour ago
- Medscape
ASCO 2025: Key Highlights in Prostate Cancer
Dr Petros Grivas surveys several exciting developments in prostate cancer research, including AI-driven biomarker analysis from the STAMPEDE trial, to identify high-risk patients who may benefit from abiraterone. He also discusses positive results from the AMPLITUDE trial, where adding niraparib to standard therapy improved radiographic progression-free survival, especially in patients with BRCA1 or BRCA2 mutations, reinforcing the need for comprehensive genomic testing. Emerging treatments such as bispecific antibodies and radioligand theranostics, including the impact of lutetium-PSMA and updates from the PSMAddition study, showed promise, though practice-changing data are still forthcoming. He emphasizes the importance of leveraging technology and community collaboration to drive progress and improve outcomes in cancer care.